截至月份: 2025年8月31日 狀態: 重新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 微創腦科學有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02172 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 呈交日期: 2025 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 重新提交 公司名稱： 微創腦科學有限公司 呈交日期： 2025年9月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | | 02172 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: 2025年8月31日 | | --- | | 狀態: 新提交 | 致：香港交易及結算所有限公司 公司名稱: 微創腦科學有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02172 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 ...

Summary of MicroPort NeuroScience Conference Call Company Overview - **Company**: MicroPort NeuroScience - **Industry**: Neurointervention Key Financial Performance - **Revenue**: 383 million RMB in H1 2025, with overseas revenue of 47.07 million RMB, a year-on-year increase of 67.4%, accounting for 12% of total revenue [2][14] - **Product Contribution**: Hemorrhagic products contributed 61% of revenue, stenosis products 30%, and acute ischemia products 8% [2][14] - **Gross Margin**: 73.4%, an increase of 1.1 percentage points year-on-year [14] - **Adjusted Net Profit Margin**: 39%, consistent with the previous year [14] - **Operating Expenses**: Total operating expenses of 148 million RMB, an increase of 11.4% [14] Market Expansion and Product Development - **Domestic Market**: Coverage expanded to approximately 3,600 hospitals, including 2,000 tertiary hospitals and all top 100 stroke centers in China [2][6] - **International Market**: Eight products commercialized in 34 countries, with significant growth in Europe, the Middle East, and Africa [2][4] - **Product Pipeline**: 26 commercialized products, with four approved in H1 2025 and 13 in research [3][14] Strategic Initiatives - **Cost Optimization**: Continuous efforts in domestic production and cost reduction, with a focus on increasing the localization rate of key materials [9][10] - **Dividend and Share Buyback**: Three rounds of dividends totaling approximately 160 million HKD and a buyback of 3.218 million shares for about 32.11 million HKD [9] - **Innovation Focus**: Emphasis on R&D with 53.54 million RMB invested, accounting for 13.8% of revenue [14] Future Outlook - **Revenue Growth Expectation**: Anticipated overall revenue growth of about 5% for 2025, with overseas revenue expected to exceed 100 million RMB, a growth of over 60% [15][16] - **Product Growth Projections**: Stenosis products expected to grow by 10%, and thrombectomy products by 40% in 2025 [17] - **Profitability Strategy**: Maintaining a gross margin above 70% despite pricing pressures from centralized procurement [18] Competitive Landscape - **Market Position**: Company remains the only profitable and dividend-paying entity in the domestic neurointervention sector [2][9] - **Market Share**: Currently holds over 10% market share in the Jing-Jin-Ji region for spring coils, with expectations to maintain this level [23] - **Challenges**: Increased competition with over 50 brands in the neurointervention market, necessitating continuous innovation and market adaptation [35] International Strategy - **Market Penetration**: Focus on establishing a presence in high-potential markets such as the U.S., Brazil, and Japan, with a projected compound annual growth rate of 30% to 50% for overseas business [31][37] - **Sales Strategy**: Direct sales model with flexible pricing strategies tailored to local economic conditions [40] Additional Insights - **Regulatory Environment**: Adapting to stricter registration requirements for new products, which may impact timelines for product launches [22] - **Emerging Markets**: Successful entry into new markets like Turkey and Egypt, with ongoing efforts to expand product offerings [5][31] This summary encapsulates the key points from the conference call, highlighting the company's financial performance, market strategies, product development, and future outlook in the neurointervention industry.

Group 1 - The company, MicroPort Scientific Corporation (02172), announced a decision to grant stock options to 63 eligible participants under a share scheme adopted on July 12, 2023 [1] - The total number of stock options granted amounts to a maximum of 402,300 shares of the company's common stock, each with a par value of $0.00002 [1] - The grant of stock options is subject to acceptance by the grantees before it becomes effective [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 MicroPort NeuroScientic Corporation 微創腦科學有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2172） 授出購股權 本公告乃根據香港聯合交易所有限公司證券上市規則（「上市規則」）第17.06A條 而作出。 微創腦科學有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董事」） 會（「董事會」）謹此宣佈，於二零二五年八月二十八日，本公司已決議根據本公 司於二零二三年七月十二日採納之股份計劃（「股份計劃」）向63名合資格參與 者（「承授人」）授出購股權（「購股權」），以合共認購最多402,300股本公司股本 中每股面值0.00002美元之本公司普通股（「股份」），惟須待承授人接納後，方可 作實。 有關購股權之詳情載列如下： – 1 – 授出日期 二零二五年八月二十八日（「授出日期」） 承授人之數目 63名承授人（全部承授人均 ...

Core Viewpoint - Micron Brain Science (02172) experienced a decline of over 5%, with a current price of HKD 13.05 and a trading volume of HKD 77.84 million [1] Financial Performance - For the first half of 2025, the company reported revenue of approximately HKD 383 million, a year-on-year decrease of 6.2% [1] - The profit attributable to equity shareholders was HKD 92.923 million, reflecting a year-on-year decline of 35.25% [1] - The interim dividend was set at HKD 0.05 per share, down from HKD 0.08 per share in the same period last year [1] International Business Growth - The company's international business continued to show strong growth, with overseas revenue reaching HKD 47.1 million, an increase of 67.4% compared to the same period last year [1] - Profit from the international business segment experienced rapid growth [1] - Sales revenue in the Asia-Pacific, Europe, Middle East and Africa (EMEA), North America, and Latin America regions all achieved varying degrees of rapid growth [1]

智通财经APP获悉，微创脑科学(02172)跌超5%，截至发稿，跌5.09%，报13.05港元，成交额7784.41万 港元。 消息面上，微创脑科学公布2025年中期业绩，收入约3.83亿元，同比减少6.2%；公司权益股东应占溢利 9292.3万元，同比减少35.25%；中期息派5港仙，上年同期派8港仙。公告指出，报告期内，该集团的国 际业务延续强劲增长态势，海外收入达4710万元，较上年同期增长67.4%，且国际业务分部利润实现高 速增长。其中，该集团在亚太地区、欧洲、中东和非洲地区(EMEA地区)、北美地区及拉美地区的销售 收入均实现不同程度的快速增长。 ...

Core Insights - Micron Brain Science (02172) reported a mid-year performance for 2025, with revenue approximately 383 million yuan, a year-on-year decrease of 6.2% [1] - The company's profit attributable to equity shareholders was 92.923 million yuan, down 35.25% year-on-year, with earnings per share at 0.16 yuan [1] International Business Performance - The international business segment continued to show strong growth, with overseas revenue reaching 47.1 million yuan, an increase of 67.4% compared to the same period last year [1] - Profits from the international business division experienced rapid growth, indicating a successful expansion strategy [1] Product and Market Expansion - As of the end of the reporting period, the company had eight products launched internationally, achieving commercialization in 34 overseas countries or regions [1] - The products cover nine countries that rank among the top ten globally in terms of neurosurgical procedures, highlighting the company's competitive positioning [1] - The company secured nine product registration certificates in various overseas markets, laying a solid foundation for scaling up international revenue [1]

Core Viewpoint - MicroPort NeuroTech (02172.HK) reported a revenue of RMB 382.9 million for the six months ending June 30, 2025, a decrease of 6.2% compared to RMB 408.2 million for the same period in 2024, primarily due to various factors affecting product sales and market dynamics [1] Revenue Breakdown - The revenue is mainly derived from hemorrhagic stroke products, carotid artery atherosclerosis products, and acute ischemic stroke products [1] - The overseas business continued to show strong growth, with revenue increasing approximately 67.4% year-on-year, and sales in the Asia-Pacific, North America, Latin America, and Europe, Middle East, and Africa regions all experienced varying degrees of rapid growth [1] - Revenue from hemorrhagic stroke products, including the spring coil series and the globally unique WILLIS intracranial covered stent, maintained rapid growth, while the market share of spring coils increased [1] - Revenue from carotid artery atherosclerosis products declined mainly due to the cessation of cooperation with original agents and the impact of centralized procurement in certain regions [1] Profitability Metrics - The company's gross profit margin was 73.4%, an increase of 1.1 percentage points from 72.3% in the same period last year, attributed to improved production efficiency [1] - The net profit recorded during the reporting period was approximately RMB 92.7 million [1] Dividend Announcement - The board of directors proposed an interim dividend of HKD 0.05 per ordinary share for the six months ending June 30, 2025 [1]